HK1208173A1 - 溴麥角環肽製劑 - Google Patents

溴麥角環肽製劑

Info

Publication number
HK1208173A1
HK1208173A1 HK15108831.9A HK15108831A HK1208173A1 HK 1208173 A1 HK1208173 A1 HK 1208173A1 HK 15108831 A HK15108831 A HK 15108831A HK 1208173 A1 HK1208173 A1 HK 1208173A1
Authority
HK
Hong Kong
Prior art keywords
bromocriptine formulations
bromocriptine
formulations
Prior art date
Application number
HK15108831.9A
Other languages
English (en)
Inventor
Anthony Cincotta
Craig Michael Bowe
Paul Clark Stearns
Laura Jean Weston
Original Assignee
Veroscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veroscience Llc filed Critical Veroscience Llc
Publication of HK1208173A1 publication Critical patent/HK1208173A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK15108831.9A 2012-04-30 2015-09-10 溴麥角環肽製劑 HK1208173A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/460,452 US8431155B1 (en) 2012-04-30 2012-04-30 Bromocriptine formulations
PCT/US2013/038655 WO2013165902A1 (en) 2012-04-30 2013-04-29 Bromocriptine formulations

Publications (1)

Publication Number Publication Date
HK1208173A1 true HK1208173A1 (zh) 2016-02-26

Family

ID=48146046

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108831.9A HK1208173A1 (zh) 2012-04-30 2015-09-10 溴麥角環肽製劑

Country Status (13)

Country Link
US (11) US8431155B1 (zh)
EP (4) EP3620155B1 (zh)
JP (1) JP6180515B2 (zh)
KR (1) KR101593360B1 (zh)
AR (1) AR091351A1 (zh)
AU (3) AU2013256558B2 (zh)
BR (1) BR112014027087B1 (zh)
CA (1) CA2872300C (zh)
ES (3) ES2972198T3 (zh)
HK (1) HK1208173A1 (zh)
MX (2) MX363670B (zh)
UY (1) UY34776A (zh)
WO (1) WO2013165902A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
EP3524248A1 (en) 2007-06-21 2019-08-14 VeroScience LLC Method of treating metabolic disorders and depression with dopamine receptor agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
EP2846767B1 (en) 2012-05-03 2022-01-26 Janssen Sciences Ireland Unlimited Company Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
AU2017254650A1 (en) 2016-04-20 2018-11-15 Veroscience Llc Composition and method for treating metabolic disorders
US10426772B2 (en) 2016-05-16 2019-10-01 Regents Of The University Of Minnesota Use of ergot alkaloids as an anthelmintic agent
JP7231255B2 (ja) 2017-10-18 2023-03-01 ヴェロサイエンス，リミテッド・ライアビリティー・カンパニー 改善されたブロモクリプチン製剤
CA3149877A1 (en) 2019-09-23 2021-04-01 Anthony H. Cincotta Method for inducing tumor regression

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659715A (en) 1986-03-07 1987-04-21 Louisiana State University And Agricultural And Mechanical College Method of inhibiting body fat stores
US4783469A (en) 1986-03-07 1988-11-08 Meier Albert H Method of inhibiting body fat stores
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US5668155A (en) 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5700800A (en) 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US6004972A (en) 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US5344832A (en) 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5585347A (en) 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5830895A (en) 1988-05-10 1998-11-03 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for the determination and adjustment of prolactin daily rhythms
US5744477A (en) 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
US5731287A (en) 1988-05-10 1998-03-24 Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
US5468755A (en) 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5006526A (en) 1988-10-17 1991-04-09 Louisiana State University Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis
IT1235053B (it) * 1989-04-07 1992-06-17 Poli Ind Chimica Spa Metodi per la preparazione di composizioni farmaceutiche a base di bromocriptina dotate di elevata stabilita' e prodotti derivanti.
CA2030174C (en) 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5696128A (en) 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
GB9421836D0 (en) * 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US5565454A (en) 1995-05-31 1996-10-15 Ergo Science, Incorporated Method for preventing intervention-associated stenosis and other symptoms associated with stenosis of blood vessels following non-bypass, invasive interventions
US5792748A (en) 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals
US5626860A (en) 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
US5877183A (en) 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040077679A1 (en) 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040220190A1 (en) 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20050054652A1 (en) 2002-07-29 2005-03-10 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20040081678A1 (en) 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
MX349134B (es) 2003-01-23 2017-07-12 Esperion Therapeutics Inc Compuestos de hidroxilo y composiciones para el manejo del colesterol y usos relacionados.
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US8137994B2 (en) 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137993B2 (en) 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
JP5190273B2 (ja) * 2005-03-04 2013-04-24 ニコメド ファーマ エイエス 連続式流動床中でのカルシウム組成物の製造方法
ES2374963T3 (es) * 2006-01-05 2012-02-23 Essentialis, Inc. Sales de agentes de apertura del canal de potasio dependiente de atp y usos de las mismas.
KR101400064B1 (ko) * 2006-04-13 2014-05-27 니폰 조키 세야쿠 가부시키가이샤 건식 직타 속붕괴성 정제
BRPI0809282B8 (pt) * 2007-04-13 2021-05-25 Dow Global Technologies Inc material granular, material de partida para uma forma de dosagem, forma de dosagem, processo de compressão direta para preparar uma forma de dosagem, uso do material granular e processo para granular um pó de polímero
US20210401824A1 (en) 2007-06-21 2021-12-30 Veroscience Llc Parenteral Formulations of Dopamine Agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
EP3524248A1 (en) 2007-06-21 2019-08-14 VeroScience LLC Method of treating metabolic disorders and depression with dopamine receptor agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US7631155B1 (en) 2007-06-30 2009-12-08 Emc Corporation Thin provisioning of a file system and an iSCSI LUN through a common mechanism
JP2011500557A (ja) * 2007-10-11 2011-01-06 マゼンス インコーポレイテッド ナフトキノン系化合物の微粒化粒子を含有する医薬組成物
JP5883382B2 (ja) * 2009-06-05 2016-03-15 ヴェロサイエンス・エルエルシー 代謝障害の治療のためのドーパミン作動薬と第一相インスリン分泌促進薬の組合せ
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
BR112012031103A2 (pt) 2010-06-08 2017-06-20 Veroscience Llc método para tratar um paciente sofrendo de um distúrbio metabólico, método para tratar pelo menos um desarranjo não-metabólico em um paciente, método para tratar pelo menos em desarranjo metabólico e pelo menos em desarranjo não-metabólico em um paciente, método para tratar pelo menos uma doença vascular em um paciente e composição farmacêutica efetiva para tratar a síndrome metabólica, diabetes tipo 2, obesidade, ou pré-diabetes
MX2013005705A (es) 2010-11-23 2013-09-16 Veroscience Llc Tratamiento terapeutico para sindrome metabolico, diabetes tipo 2, obesidad, o prediabetes.
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
CA2915405A1 (en) 2013-06-13 2014-12-18 Veroscience Llc Compositions and methods for treating metabolic disorders
AU2017254650A1 (en) 2016-04-20 2018-11-15 Veroscience Llc Composition and method for treating metabolic disorders
US20170340271A1 (en) 2016-05-26 2017-11-30 Veroscience Llc Methods for identifying responders to dopaminergic neuronal enhancing therapies for the treatment of elevated heart rate and metabolic or cardiovascular conditions
JP7231255B2 (ja) 2017-10-18 2023-03-01 ヴェロサイエンス，リミテッド・ライアビリティー・カンパニー 改善されたブロモクリプチン製剤
CA3149877A1 (en) 2019-09-23 2021-04-01 Anthony H. Cincotta Method for inducing tumor regression

Also Published As

Publication number Publication date
US20170340632A1 (en) 2017-11-30
ES2755081T3 (es) 2020-04-21
CA2872300A1 (en) 2013-11-07
EP4342536A3 (en) 2024-06-26
US20200276193A1 (en) 2020-09-03
US20130287848A1 (en) 2013-10-31
CA2872300C (en) 2016-08-16
US20240131026A1 (en) 2024-04-25
BR112014027087A2 (pt) 2017-06-27
US8613947B2 (en) 2013-12-24
EP4342536A2 (en) 2024-03-27
US9993474B2 (en) 2018-06-12
US20140187560A1 (en) 2014-07-03
US9700555B2 (en) 2017-07-11
US9522117B2 (en) 2016-12-20
UY34776A (es) 2013-11-29
EP3620155A1 (en) 2020-03-11
MX2019003619A (es) 2019-07-18
US10688094B2 (en) 2020-06-23
US8431155B1 (en) 2013-04-30
US20210228576A1 (en) 2021-07-29
AU2013256558A1 (en) 2014-12-18
EP2844229B1 (en) 2019-09-11
US9192576B2 (en) 2015-11-24
KR20150006461A (ko) 2015-01-16
ES2902573T3 (es) 2022-03-29
AU2016202572A1 (en) 2016-05-19
WO2013165902A1 (en) 2013-11-07
BR112014027087B1 (pt) 2021-03-02
US20190343833A1 (en) 2019-11-14
US10307421B2 (en) 2019-06-04
EP2844229A1 (en) 2015-03-11
MX363670B (es) 2019-03-29
AU2016202572B2 (en) 2018-02-01
AU2013256558B2 (en) 2016-01-28
AU2018203021B2 (en) 2020-02-06
US11666567B2 (en) 2023-06-06
US20170020871A1 (en) 2017-01-26
AR091351A1 (es) 2015-01-28
KR101593360B1 (ko) 2016-02-11
US20180263978A1 (en) 2018-09-20
US11000522B2 (en) 2021-05-11
EP3620155B1 (en) 2021-10-20
JP2015515984A (ja) 2015-06-04
JP6180515B2 (ja) 2017-08-16
EP3960160A1 (en) 2022-03-02
EP3960160B1 (en) 2023-12-06
ES2972198T3 (es) 2024-06-11
US20160038424A1 (en) 2016-02-11
MX2014013158A (es) 2015-07-14
AU2018203021A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
HK1208173A1 (zh) 溴麥角環肽製劑
GB2506426B (en) Composition
PL2804487T3 (pl) Kompozycja
ZA201500519B (en) Composition
HK1207989A1 (zh) 組合物
EP2878295A4 (en) COMPOSITION
GB201218954D0 (en) Composition
GB2498803B (en) Composition
HRP20190326T1 (hr) Pripravak
HK1199198A1 (zh) 組合物
GB201206035D0 (en) Composition
ZA201407419B (en) Composition
EP2837670A4 (en) COMPOSITION CONTAINING FLUOROBIPHENYL
HK1210966A1 (zh) 米索前列醇組合物
HRP20190033T1 (hr) Pripravak
EP2910538A4 (en) AGENT COMPOSITION GENERATING GAS
EP2910537A4 (en) AGENT COMPOSITION GENERATING GAS
GB201209597D0 (en) Composition
GB201208133D0 (en) Composition
GB201311517D0 (en) Composition
GB201219383D0 (en) Composition
GB201218195D0 (en) Composition
HK1204230A1 (zh) 組合物
GB201206178D0 (en) Formulations
GB201223526D0 (en) Composition